Comparison of Gritstone Oncology Inc. (GRTS) and Novo Nordisk A/S (NYSE:NVO) – MS Wkly

Both Gritstone Oncology Inc. (NASDAQ:GRTS) and Novo Nordisk A/S (NYSE:NVO) are each others competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings & Valuation

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Liquidity

The Current Ratio of Gritstone Oncology Inc. is 9.6 while its Quick Ratio stands at 9.6. The Current Ratio of rival Novo Nordisk A/S is 1 and its Quick Ratio is has 0.7. Gritstone Oncology Inc. is better equipped to clear short and long-term obligations than Novo Nordisk A/S.

Analyst Ratings

In next table is given Gritstone Oncology Inc. and Novo Nordisk A/Ss ratings and recommendations.

Competitively Novo Nordisk A/S has an average target price of $400, with potential upside of 668.79%.

Institutional & Insider Ownership

Roughly 65% of Gritstone Oncology Inc. shares are held by institutional investors while 9.8% of Novo Nordisk A/S are owned by institutional investors. Insiders held roughly 7.27% of Gritstone Oncology Inc.s shares. Comparatively, 26.4% are Novo Nordisk A/Ss share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Gritstone Oncology Inc. has -32.04% weaker performance while Novo Nordisk A/S has 4.02% stronger performance.

Summary

Novo Nordisk A/S beats Gritstone Oncology Inc. on 11 of the 12 factors.

Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Comparison of Gritstone Oncology Inc. (GRTS) and Novo Nordisk A/S (NYSE:NVO) - MS Wkly